Xenon Pharmaceuticals
XENE
154 hedge funds and large institutions have $1.96B invested in Xenon Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 59 increasing their positions, 41 reducing their positions, and 23 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 41
21% more capital invested
Capital invested by funds: $1.62B → $1.96B (+$345M)
13% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 23
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
2% more funds holding
Funds holding: 151 → 154 (+3)
0.13% less ownership
Funds ownership: 93.49% → 93.36% (-0.13%)
74% less call options, than puts
Call options by funds: $1.63M | Put options by funds: $6.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$29.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$26.6M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$26.3M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$18M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$30.2M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$25.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$18.2M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$13.7M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$10.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PFGIA
176
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
| – | -$1K | -35 | Closed |
|
177
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$36 | +1 | New |
|
XENE Hedge Fund Activity: Q3 2022 in Review
154 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2022, worth a combined $1.96B — up 21% from $1.62B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new XENE positions and 23 closed out — a net gain of 3 holders — while 59 added to existing stakes and 41 trimmed.
The largest buyer was Marshall Wace, adding an estimated $29.5M. The largest seller was Morgan Stanley, cutting an estimated $30.2M.
- 154 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2022, up from 151 in Q2 2022.
- Funds reported $1.96B of Xenon Pharmaceuticals stock for Q3 2022, up 21% quarter-over-quarter.
- 26 funds opened new Xenon Pharmaceuticals positions in Q3 2022 and 23 closed out, a net change of +3 holders.
- The largest Xenon Pharmaceuticals buyer in Q3 2022 was Marshall Wace, an estimated $29.5M added.
- The largest Xenon Pharmaceuticals seller in Q3 2022 was Morgan Stanley, an estimated $30.2M sold.
Based on aggregated 13F filings for Q3 2022.